Expertise in
6
conditions

Omar Perbellini

Vicenza, IT 
Expertise in
6
conditions
Vicenza, IT 

Overview

Omar Perbellini practices practicing medicine in Vicenza, Italy.

Mr. Perbellini is highly rated in 6 conditions, according to our data. His clinical expertise encompasses Mast Cell Activation Syndrome (MCAS), Systemic Mastocytosis, Chronic Lymphocytic Leukemia (CLL), and Chronic B-Cell Leukemia (CBCL).

He is actively involved in clinical research, co-authoring 46 peer reviewed articles and participating in 2 clinical trials.

Gender

Male

Locations

Vicenza, 36100, Italy
Other Locations
Catania, 95123, Italy
Verona, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Indolent Non Follicular Lymphomas Prognostic Project - Prospective Collection of Data of Possible Prognostic Relevance in Patients With Indolent Non-follicular B-CELL Lymphomas
Indolent Non Follicular Lymphomas Prognostic Project - Prospective Collection of Data of Possible Prognostic Relevance in Patients With Indolent Non-follicular B-CELL Lymphomas
Enrollment Status: Completed
Publish Date: August 08, 2025
Intervention Type: Other
The Benefit/Risk Profile of Pegylated Proline-Interferon Alpha-2b (AOP2014) Added to the Best Available Strategy Based on Phlebotomies in Low-risk Patients With Polycythemia Vera (PV). The Low-PV Randomized Trial
The Benefit/Risk Profile of Pegylated Proline-Interferon Alpha-2b (AOP2014) Added to the Best Available Strategy Based on Phlebotomies in Low-risk Patients With Polycythemia Vera (PV). The Low-PV Randomized Trial
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug, Procedure
Study Drugs: AOP2014, Acetylsalicylic acid
Study Phase: Phase 2
View 1 Less Clinical Trial

46 Total Publications

Early Ibrutinib Dose Modifications in CLL: A Post Hoc Analysis of the Real-World EVIdeNCE Study.
Early Ibrutinib Dose Modifications in CLL: A Post Hoc Analysis of the Real-World EVIdeNCE Study.
Journal: Cancers
Published: January 08, 2026

Frequently Asked Questions about Omar Perbellini

Is Omar Perbellini a top-rated expert for Mast Cell Activation Syndrome (MCAS)?

MediFind is an objective health platform that identifies experts based on real-world data. Omar Perbellini is classified as an Distinguished expert for Mast Cell Activation Syndrome (MCAS), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Omar Perbellini participate in research or clinical trials?

Yes. Omar Perbellini has published 46 articles and abstracts on conditions like Mast Cell Activation Syndrome (MCAS). You can view a list of Omar Perbellini's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Perbellini's expertise for a condition
ConditionClose
    View All 13 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile